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SUMMARY
Neurofibromatosis type 1 (Nf1) mutation predisposes to benign peripheral nerve (glial) tumors called neuro-
fibromas. The point(s) in development when Nf1 loss promotes neurofibroma formation are unknown. We
show that inactivation ofNf1 in the glial lineage in vitro at embryonic day 12.5 + 1, but not earlier (neural crest)
or later (mature Schwann cell), results in colony-forming cells capable of multilineage differentiation. In vivo,
inactivation of Nf1 using a DhhCre driver beginning at E12.5 elicits plexiform neurofibromas, dermal neuro-
fibromas, and pigmentation. Tumor Schwann cells uniquely show biallelic Nf1 inactivation. Peripheral nerve
and tumors contain transiently proliferating Schwann cells that lose axonal contact, providing insight into
early neurofibroma formation. We suggest that timing of Nf1 mutation is critical for neurofibroma formation.INTRODUCTION
Neurofibromatosis type 1 (NF1) is an autosomal dominant in-
herited disease, affecting 1 in 3500 individuals worldwide. Nearly
all (90% of) NF1 patients develop plexiform and/or dermal neu-
rofibromas (Friedman, 1999), composed of a mixture of axons,
Schwann cells, fibroblasts, perineurial cells, and mast cells.
Diffuse plexiform neurofibromas develop in childhood and often
extend deeply along nerves and can involve all levels of skin, fas-
cia, muscle, bone, and even viscera, whereas dermal (variously
designated dermal/cutaneous and subcutaneous in the literature
and which we group as dermal) neurofibromas associated with
small nerve branches mainly develop with puberty and into
adulthood (Huson, 1998). Schwann cells are believed to be the
primary pathogenic cells in neurofibromas because they showbiallelic mutation at NF1 and cell autonomous angiogenic and
invasive properties (Serra et al., 1997; Sheela et al., 1990). How-
ever, other cell types present in tumors in the NF1+/ state also
show cell autonomous defects (Cichowski et al., 2003; Kim
et al., 1995, 1997; Yang et al., 2003). The role of these cells in
human neurofibromas is not known.
The NF1 tumor suppressor gene, located on human chromo-
some 17q11.2, encodes a Ras GTPase activating protein (GAP).
Ras is hyperactivated in NF1-deficient human neurofibromas
and Schwann cells lacking NF1 (Cichowski and Jacks, 2001;
DeClue et al., 1992; Guha et al., 1996; Sherman et al., 2000).
Mutations affecting NF1 and Ras also induce a global negative
feedback response that potently suppresses Ras and/or its effec-
tors (Courtois-Cox et al., 2006). Nomenclature for mouse nerve
tumors was defined at a consensus conference; mouse tumorsSIGNIFICANCE
Neurofibromatosis type 1 (NF1) is an autosomal dominant inherited disease, affecting 1:3500 individuals worldwide. Nearly
all (90%) of NF1 patients develop plexiform and/or dermal neurofibromas composed of axons, Schwann cells, fibroblasts,
perineurial cells, endothelial cells, and mast cells. Schwann cells are believed to be the primary pathogenic cells in neuro-
fibromas because they show biallelic mutation at NF1. However, other cell types present in tumors, in the NF1+/ state, also
show cell autonomous defects and can contribute to neurofibroma formation. Our data support an additional mechanism
for tumor development, in which loss of Nf1 at the correct time in development facilitates tumor formation in a wild-type
environment.Cancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc. 105
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Neurofibroma Formation in Miceare preceded by a genetically engineered mouse (GEM) designa-
tion (Stemmer-Rachamimov et al., 2004). GEM-neurofibromas
and their aggressive derivates, GEM-peripheral nerve sheath
tumors (GEM-PNST), developed by 3 months in visible locations
(ear and tail) when the human T-lymphotropic virus type 1 trans-
regulatory gene, tax, was expressed under the control of a viral
long terminal repeat. Tax decreased Nf1 transcription though
an element upstream of the Nf1 start site (Feigenbaum et al.,
1996). In transgenic mouse using a CAMKinaseII promoter to
drive expression of an activated N-Ras allele, mice developed
GEM dermal neurofibromas (Saito et al., 2007). More accu-
rately, Nf1-driven models mimicking as closely as possible hu-
man dermal and plexiform neurofibroma formation are needed
to clarify mechanisms underlying tumorigenesis and to provide
a platform for therapeutic testing.
Nf1/ mouse embryos die at E13.5, and Nf1+/ mice do
not develop neurofibromas (Brannan et al., 1994; Jacks et al.,
1994). Nf1+/ mice serve as an important therapeutic model for
GEM-PNST when crossed to p53 mutant mice (Cichowski
et al., 1999; Vogel et al., 1999). Chimeric mice partially composed
of Nf1 homozygous (Nf1/) embryonic stem cells developed
numerous neurofibromas resembling human plexiform neurofi-
bromas, but not dermal neurofibromas (Cichowski et al., 1999).
A breakthrough came from conditionally ablating Nf1 in the
Schwann cell lineage, using Krox20-Cre (Zhu et al., 2002). This
promoter is expressed transiently in developing glial and neuro-
nal cells in the boundary cap at E10.5 and developing peripheral
nerve cells at E15.5. Boundary cap cells, but not E15.5 nerve
cells, have stem cell properties (Aquino et al., 2006; Maro et al.,
2004; Stemple and Anderson, 1993; Zorick et al., 1999). In
the Nf1flox/flox; Krox20-Cre model, while neurofibromas did not
form, microscopic regions of nerve hyperplasia were noted. On
the Nf1+/ background, all mice developed GEM-neurofibroma
of the nerve roots and cranial nerves by 15 months of age (Zhu
et al., 2002). Based on this data and because most NF1 patients
have somatic cells heterozygous for NF1 mutation, it was pro-
posed that Nf1+/ endothelial cells, fibroblasts, Schwann cells,
and/or mast cells are required for neurofibroma formation.
The existence of patients who are somatic mosaic forNF1mu-
tations and the occurrence of neurofibromas in otherwise normal
individuals suggested that, at least in some cases, aNF1+/ envi-
ronment might not be required for neurofibroma formation. Here,
we evaluated another factor, developmental time, in neurofi-
broma formation. We report that inactivation of Nf1 at embryonic
day 12.5 (E12.5) in developing glial cells in vitro elicits formation of
colonies containing bipotent precursors and in vivo recapitulates
human neurofibroma formation in a wild-type background.
RESULTS
Loss of Nf1 in E12.5 Glial Cells
Promotes Colony Formation In Vitro
To define the point(s) in peripheral glial cell lineage(s) at which
loss of Nf1 might amplify a cell population, we infected cells
from mice with a targeted insertion of loxP sites flanking exon
31 of the mouse Nf1 gene with adenovirus-mediated Cre recom-
binase (adeno-Cre). All trunk peripheral glial cells are derived
from the neural crest, a multipotent cell population. Trunk neural
crest cells develop into boundary cap cells in the region of the106 Cancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc.dorsal and ventral roots, satellite cells associated with neuronal
cell bodies in the peripheral ganglia, Schwann cell precursors,
and then Schwann cells in the nerve proper (Jessen and Mirsky,
2005; Maro et al., 2004). We effected Cre-recombinase medi-
ated recombination of the floxed Nf1 gene in cultured cell prep-
arations from E12.5 dorsal root ganglia (DRG) 16 hr after plating
cells. We chose the dorsal root ganglia from mice together with
associated nerve roots and developing nerves for these studies
as they contain all classes of trunk peripheral glia. In these
cultures (E12.5 + 1 DIV), we observed colonies in preparations
from single embryos after 1 to 2 weeks in vitro (Figures 1A and
1B). In three independent experiments, an average of 58 colonies
Figure 1. Acute Loss ofNf1 in Dorsal Root Ganglion Cells at E12.5+1
Results in Colony Formation In Vitro
(A) Quantification of colonies resulting from acute loss of Nf1 in E8.5 neural
tube-derived crest cells, E12.5 dorsal root ganglion (DRG) cells, or differenti-
ated Schwann cells (denoted E18.5) derived from Nf1flox/flox mice cells. A
few colonies were observed in the E12.5 DRG cells infected by adeno-GFP
but could not be expanded (mean ± SD). (B) Phase micrograph of expandable
adherent colonies resulting from E12.5 DRG cells infected by adeno-Cre. (C)
Adeno-Cre-mediated recombination confirmed by PCR. N, Nf1 flox allele;
R-Cre, recombined Nf1 allele; MOI, multiplicity of infection. Cells replated
from colonies after E12.5 DRG-derived recombination (D), or adeno-GFP (E)
were immunostained with anti-Blbp and detected with a fluorescently tagged
anti-rabbit antibody. (F and G) Differentiation of E12.5 DRG-derived colony-
forming cells in vitro. E12.5 DRG-derived colonies were replated and cells
were cultured under gliogenic and smooth muscle/myofibroblast generating
culture conditions for 12 days, were immunostained with anti-MBP (F) or
anti-SMA (G) antibodies, and staining was detected with appropriate second
antibodies. Scale bars: (B), 50 mm; (D) and (E), 26mm; (F) and (G), 15mm.
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adeno-Cre, while 8 colonies were observed when cells were in-
fected with adeno-GFP; only cells infected with adeno-Cre could
be replated and expanded for up to 5 passages in DMEM: F-12
(1:1) with N2 supplements medium (data not shown). In contrast,
induced loss of Nf1 in neural tube-derived neural crest cells
(E8.5 + 1 DIV) did not elicit colonies (Figure 1A). Likewise, no col-
onies were identified when Nf1flox/flox cells from E12.5 DRG were
allowed to differentiate into Schwann cells (using a 7 day expo-
sure to b heregulin) and then exposed to adenoviral-Cre recom-
binase (Figure 1A). At each developmental stage, cultures in-
fected with adeno-GFP showed 80%–90% of cells infected by
virus. Cultured postmigratory neural crest cells at the point of ad-
eno-Cre infection cells were P75+, Lineage (Gfap, S100b, b3Tub)
negative cells with the exception of rare SMA+ cells (fibroblasts);
mixed E12.5 DRG cells are neurons, a few fibroblasts, and pro-
genitors; and Schwann cell cultures are 98%–99% S100b+
Schwann cells (data not shown). Cre-mediated Nf1 recombina-
tion efficiency was confirmed by PCR (Figure 1C).
Staining of cells from E12.5-derived colonies demonstrated
that they expressed Blbp (Figure 1D), a marker of the Schwann
cell precursor and immature Schwann cell stages (Jessen and
Mirsky, 2005). Cells present innerveat the Schwanncell precursor
stage can show multilineage differentiation in vitro (Joseph et al.,
2004; Morrison et al., 1999; White et al., 2001). To test if the cells in
colonies are multipotent, we cultured E12.5 colony forming cells
under conditions that drive cells toward neuron, Schwann cell,
or fibroblast differentiation (Fernandes et al., 2004; Joseph
et al., 2004). While no cells expressed lineage markers before
treatment, 12 days later marker analysis by immunostaining indi-
cated that >50% differentiated into either elongated glial cells
(Myelin basic protein, Mbp+) in response to b-heregulin and
forskolin, or large flat fibroblasts (SMA+) in response to TGFb1
(Figures 1F and 1G). No b-tubulin+ neurons formed even after ex-
posure to FGF2 and then neurotrophins. Thus, loss ofNf1 in dorsal
root ganglion cells E12.5 + 1 DIV, but not earlier or later, caused
colony formation, and cells within colonies could form fibroblasts
and Schwann cells. Further analysis will be necessary to assess
clonal relationships among derivatives.
DhhCre Is Expressed in Boundary Cap Cells and
Schwann Cell Precursors Beginning at E12.5 In Vivo
To test if loss ofNf1 post-neural crest and before terminal glial cell
differentiation might elicit a tumorigenic phenotype in vivo, we
chose the DhhCremouse in which Cre recombinase is expressed
from Desert Hedgehog (Dhh) regulatory sequences to elicit re-
combination of the Nf1flox/flox allele. This promoter has been re-
ported to drive expression beginning at E12.5 in developing glial
cells, but not neural crest cells, neurons, or CNS cells (Jaegle
et al., 2003; Joseph et al., 2004). The DhhCre allele was also
bred to an Nf1flox/flox background EGFP reporter mouse in which
the CMV-b actin promoter and loxP flanked CAT gene are up-
stream of the enhanced green fluorescent protein cassette (Naka-
mura et al., 2006). Hereafter, this allele is designated EGFP. To
precisely define the onset of DhhCre expression in populations
of peripheral glia, we bred Nf1flox/flox background EGFP mice
(Nf1flox/flox;EGFP) toNf1flox/+;DhhCre transgenic mice. We isolated
embryos from these crosses and viewed the spinal cordwithnerve
roots, DRGs, and peripheral nerve directly under fluorescenceoptics or after staining cryosections with anti-GFP. No green cells
(EGFP+) were detected in embryos at embryonic days 11.5 in
early-developing boundary cap cells (Figure 2A). At day E12.5,
EGFP+ cells were present in the dorsal and ventral root boundary
cap zones and proximal peripheral nerve, but not within the DRG
(Figures 2B and 2K). In adult mice, EGFP+ cells were present in the
DRG, peripheral nerve, and nerve roots (Figures 2C and 2M).
These studies were done in the Nf1flox/flox background, so EGFP
expression might have been altered due to Nf1 recombination.
However, our data are completely consistent with a previous re-
port thatDhh is not expressed in the neural crest and is expressed
beginning at E12.5 in the peripheral nerve (Jaegle et al., 2003).
A few cells in the dorsal root ganglion were also EGFP+. These
cells were S100b+;Gfap Schwann cells (Figure 2D–F). b-
tubulin+ neurons were EGFP-negative (Figures 2H–2J). The peri-
neurium surrounding the nerve was EGFP negative at postnatal
day 1 (Figure 2L) and postnatal day 90 (Figure 2M). We also an-
alyzed the DhhCre-induced recombination efficiency in dissoci-
ated P1 sciatic nerve cells by FACS analysis. We found 19.9% of
the total live cells were EGFP positive (data not shown). About
80% of cells in nerve are endoneurial Schwann cells, and about
10% are endoneurial fibroblasts (Asbury, 1967). Thus about
20%–30% of the endoneurial cells (Dhh expressing) showed
Cre-mediated recombination of the EGFP allele. Taken together,
the data demonstrate the specificity of the transgene for post-
neural crest developing glial cells and predict that DhhCrewill ef-
fect recombination ofNf1 in glial cells at the embryonic Schwann
cell stage in peripheral nerve and in boundary cap glia, but not in
satellite cells. We monitored Cre-inducedNf1 flox recombination
by PCR. PCR DNA analysis of brain, spinal cord, lung, heart,
liver, and spleen and sciatic nerve indicated that the peripheral
nerve showed robust levels of recombination. The variable and
low level of recombination in the other tissues is consistent
with published data (Jaegle et al., 2003) and may indicate the
presence of peripheral nerves in these tissues (Figure 2N).
Loss of Nf1 in Schwann Cells at E12.5 Is Sufficient
to Develop both Plexiform and Dermal Neurofibromas
To test whether DhhCre-mediated loss of Nf1 could elicit neuro-
fibroma formation, we bred Nf1flox/+;DhhCre mice to Nf1flox/flox
mice and obtained Nf1flox/flox;DhhCre mice in the expected Men-
delian ratios. The life span of Nf1flox/flox;DhhCre mice was greatly
reduced. When Nf1flox/flox;DhhCre mice (n = 28) were aged using
littermates as controls, we found thatNf1flox/flox;DhhCremice be-
gan to die at 5.5 months. All Nf1flox/flox;DhhCre mice in the cohort
required sacrifice by 13 months of age, while littermate controls
remained healthy except that four mice were sacrificed with se-
vere dermatitis; these mice were excluded from the control
group. Kaplan-Meier analysis of survival data is shown in
Figure 3A. Four to eight weeks preceding death, Nf1flox/flox;Dhh-
Cre mice became paralyzed in one or both hindlimbs. Eight of
28 (28.6%) Nf1
flox/flox
;DhhCre mice were paralyzed at the age of
6 months. Mice required sacrifice due to lethargy, weight loss,
and/or dehydration secondary to paralysis that correlated with
tumor formation (Table 1 and Movie S1).
We performed gross dissections of each Nf1flox/flox;DhhCre
mouse to determine whether tumors were present. The peripheral
and cranial nerve trunks and nerve roots were all significantly en-
larged in every animal. An exception was the optic nerve, in whichCancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc. 107
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(data not shown). An example of nerve enlargement in spinal
nerve roots is shown in Figure 3C.
Figure 2. The DhhCre Driver Elicits Recombination Beginning at
E12.5 in Boundary Cap Cells and Embryonic Schwann Cells
(A–C) Cryostat sections from Nf1flox/flox;DhhCre;EGFP embryos dissected at
E11.5 (A), E12.5 (B), and a section through spinal cord, nerve roots, and periph-
eral nerve at postnatal day 165 (C). Sections were stained with anti-EGFP an-
tibody. (B) Arrows show position of EGFP+ dorsal root (BC-Dr) and ventral root
(BC-Vr) boundary cap cells adjacent to the neural tube (Nt). The position of the
largely unstained dorsal root ganglion (Drg) is marked, and some green cells
are visible lateral to the DRG in the proximal nerve (PN).
(D–J) Confocal analysis of adult DRG showing EGFP+ cells are S100b+ (D),
Gfap-negative (G) and b(III)-Tubulin-negative (H). YZ view (E) and XZ view (F)
of cell indicated by arrow in (D). YZ view (I) and XZ view (J) of cell indicated
by arrow in (H). Note Gfap-positive (red) astrocytes in the spinal cord (G) and
b(III)-Tubulin-positive (red) DRG neurons and spinal cord fibers (H). (K)– (M)
are gross images. (K) A developing spinal cord (E 12.5) with EGFP+ root cells
is shown. (L) A postnatal day 1 sciatic nerve is shown. (M) Strong expression is
retained in P90 sciatic nerves. (L and M) Endoneurium containing Schwann
cells is EGFP+ (double-headed black arrow) and perineurium (adjacent to
white arrows) is negative. (N) DNA (50 ng) isolated from designated tissues
from a representative adult Nf1flox/flox;DhhCre mouse was PCR amplified. An
ethidium bromide-stained gel demonstratesNf1 recombination in sciatic nerve
using the DhhCre driver with little recombination in other organs.
FL/FL = Nfl flox allele. Scale bars: (A)–(C) and (K)–(M), 26mm; (D)–(J), 20mm.108 Cancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc.We detected visible plexiform tumors at gross dissection of
each Nf1flox/flox;DhhCre mouse (n = 28; Table 1). Although
DhhCre is expressed in Sertoli cells, we did not observe any
tumors in testis (data not shown). The plexiform tumor number
ranged from three to 24 per mouse. Most large plexiform tumors
were close to dorsal root ganglia, predominately at lower cervical
or upper thoracic levels, accounting for paralysis. We found
dermal neurofibromas in 13 of 28 (46.4%) of Nf1flox/flox; DhhCre
mice (Figures 3D and 3E), with older mice having increased num-
bers of dermal neurofibromas. Most dermal tumors were located
under the dermal muscle layer in the back in the thoracic and
lumbar areas. Specifically, in one five month old mouse one
dermal tumor was found. At 6 months, one mouse had 3 dermal
tumors. At 8 months, one mouse had >5 dermal tumors. At
Figure 3. Nf1flox/flox;DhhCre Mice Show Early Lethality and Develop
Tumors
(A) Kaplan-Meyer survival curve. Red, Nf1flox/flox;DhhCre (n = 28); blue,
Nf1flox/+;DhhCre (n = 20); green, Nf1flox/flox (n = 9); brown, Nf1flox/+ (n = 8). To
facilitate view of control mouse survival, blue, green, and brown lines are
shown offset.
(B–F) Gross dissections of tumors and areas of pigmentation in
Nf1flox/flox;DhhCre mice. In gross images (B)–(E), a ruler showing 1 mm mark-
ings is included. (B) Nf1flox/flox (wild-type) spinal cord from a 9-month-old
mouse, with pairs of spinal roots attached. (C) A similar region from an
Nf1flox/flox;DhhCre mouse, showing three paraspinal GEM-neurofibromas
(white arrows) and spinal cord compression. (D and E) Dermal GEM-neurofi-
bromas (white arrows) in Nf1flox/flox;DhhCre mice in anterior (D) and lateral
views (E). (F) Pigmentation was often detected on the surface tumors or adja-
cent to tumor; a dramatic example is shown. White arrows point to black
pigmentation. Scale bars, 1 mm.
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9Table 1. Tumor Phenotype of Nf1 flox/flox;DhhCre Mice
ID No. Sex Background
Age at
Sacrifice
Tumor
Grade
Paralysis First
Appears (Months)
Months to
Sacrifice
Reason for
Sacrifice
Plexiform
Neurofibromas
Dermal
Neurofibromas
NFC407 F 129/BL 6/FVBN 9.2 Ia 7.1 2.1 paralysis Y N
NFC412 F 129/BL 6/FVBN 7.6 Ia 4.8 2.8 paralysis Y Y
NFC421 M 129/BL 6/FVBN 11.0 I 8.1 2.9 paralysis+ dermatitis Y N
NFC422 F 129/BL 6/FVBN 10.8 Ia 8.2 2.6 paralysis Y Y
NFC423 M 129/BL 6/FVBN 7.6 I 5.5 2.1 found dead Y N
NFC425 F 129/BL 6/FVBN 5.6 I 5.1 0.5 paralysis Y Y
NFC426 M 129/BL 6/FVBN 11.0 I 7.1 3.9 paralysis+ dermatitis Y Y
NFC430 M 129/BL 6/FVBN 7.4 I/IIa 4.7 2.7 paralysis Y Y
NFC434 F 129/BL 6/FVBN 8.2 Ia 6.1 2.1 paralysis Y N
NFC436 F 129/BL 6/FVBN 9.2 Ia 8.1 1.1 paralysis Y N
NFC443 F 129/BL 6/FVBN 9.2 I 7.7 1.5 paralysis Y N
NFC446 F 129/BL 6/FVBN 7.8 I 7.0 0.8 paralysis Y N
NFC450 M 129/BL 6/FVBN 9.4 I 7.0 2.4 paralysis Y N
NFC454 F 129/BL 6/FVBN 7.8 I 6.2 1.6 paralysis Y N
NFC459 M 129/BL 6/FVBN 8.4 I 7.2 1.2 paralysis Y N
NFC470 F 129/BL 6/FVBN 12.5 Ia 10.6 1.9 paralysis +
abdominal tumor
Y Y
NFC473 M 129/BL 6/FVBN 5.4 Ia 5.3 0.1 paralysis Y Y
NFC477 M 129/BL 6/FVBN 9.8 Ia 8.1 1.7 paralysis Y N
NFC478 F 129/BL 6/FVBN 8.2 I 6.7 1.5 paralysis Y N
NFC493 M 129/BL 6/FVBN 12.5 I 11.0 1.5 paralysis Y Y
NFC495 F 129/BL 6/FVBN 7.1 Ia 5.3 1.8 paralysis Y N
NFC502 M 129/BL 6/FVBN 12.6 Ia 10.0 2.6 paralysis Y Y
NFC512 M 129/BL 6/FVBN 11.3 Ia 8.0 3.3 paralysis+ dermatitis Y Y
NFC516 M 129/BL 6/FVBN 8.9 I 8.7 0.2 paralysis+ dermatitis Y Y
NFC519 M 129/BL 6/FVBN 9.7 I 5.5 4.2 lethargy + paralysis Y N
NFC528 M 129/BL 6/FVBN 6.9 Ia 5.5 1.4 paralysis Y Y
NFC534 M 129/BL 6/FVBN 11.8 I 11.0 0.8 skin ulcer + dermatitis Y Y
NFC536 M 129/BL 6/FVBN 7.6 I 6.1 1.5 paralysis Y N
The table summarizes the sex; strain background (note that the FVB/N deriving from theDhhCre allele was rederived onto CD1 [see text for details]); age
paralysis; months from partial paralysis to sacrifice; reason for sacrifice; at autopsy, gross presence of plexiform GEM-neurofibroma; at autopsy, gro
autopsy, gross presence of pigmentation; and at autopsy, location of plexiform GEM-neurofibroma. Y, yes; N, no.
a S100b stain. All cases analyzed for S100b stain were positive for S100b staining.
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Neurofibroma Formation in Mice10 months, 3 mice each had numerous dermal tumors, and by
>11 months, 7 of 8 showed numerous dermal tumors. Two tu-
mors protruded through the epidermis. These tumors, as in NF1
patients, do not contribute to mortality (Table 1). We also found
pigmentation overlying the dorsal aspect of the spinal cord or
tumors in 11 of 28 (39.3%) Nf1flox/flox;DhhCre mice (Figure 3F).
Melanocytes and Schwann cells are both derived from the neural
crest. The presence of pigmentation in these mice is consistent
with Dhh-mediated loss of Nf1 in a common progenitor.
We performed histological analysis on plexiform and dermal
tumors and used published criteria to define grades of mouse
peripheral nerve tumors (Stemmer-Rachamimov et al., 2004).
Paraffin sections from >40 tumors were evaluated by H&E and
S100b staining. Plexiform neurofibromas involved large nerve
trunks, and showed classic neurofibroma histology (Grade I)
with a heterogeneous cell population containing S100b+ cells
and S100b cells (Figures 4A and 4B). The dermal tumors
were also histologically classic neurofibroma grade I, with
numerous spindle shaped S100b+ cells (Figures 4C and 4D).
Nf1flox/flox;DhhCre mouse tumors contain abundant collagen
(Figure 4E) and many mast cells (Figure 4F). Only one of the
40 tumors analyzed showed areas of hypercellularity that
Figure 4. Nf1flox/flox;DhhCre Mice: Histological and Electron
Microscopic Analysis
(A and C) Paraffin-embedded tissue sections from plexiform and dermal GEM-
neurofibromas stained with hematoxylin and eosin (H&E). (B and D) Adjacent
sections were stained with anti-S100b antibody visualized with DAB [brown].
(E) Plexiform neurofibroma sections stained with Masson’s trichrome showing
abundant collagen (blue) in the tumor. (F) Toluidine blue staining showing
metachromatic mast cell infiltration (black arrows). Electron micrographs of
plexiform (G) and dermal GEM-neurofibromas (H); small black arrowheads
point to nonmyelinating Schwann cells that are apparently not wrapping mul-
tiple axons. White arrows in (G) and (H) indicate intact myelinated fibers. In (I),
a higher magnification electron micrograph shows abundant collagen deposi-
tion (C) and prominent Schwann cell cytoplasmic processes identified by con-
tinuous basal lamina (black arrows). Fibroblasts are identified by prominent in-
tracellular vesicles, prominent endoplasmic reticulum, and patchy basal
lamina. Scale bars: (A)–(F), 20 mm; (G) and (H), 10mm; (I), 1mm.110 Cancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc.may correspond to early malignant transformation (grade 1/2)
(Table 1).
To better define the cells within these tumors, we performed
ultrastructural analysis on dermal and plexiform lesions. As
shown in Figures 4G–4I, the tumors contained abundant colla-
gen and prominent Schwann cell cytoplasmic processes as
defined by continuous basal lamina. Remak bundles, groups of
small axon diameter within membrane delineated cytoplasm of
a nonmyelinating Schwann cell, were disrupted, but myelinated
fibers appeared normal. Mast cells were confirmed by presence
of intracellular granules. Fibroblasts, identified by numerous in-
tracellular vesicles and patchy basal lamina, were also present.
The data demonstrate a close similarity between the lesions in
Nf1flox/flox;DhhCre mouse tumors and previously described
human neurofibromas (Dickersin, 1987). These results indicated
that loss of Nf1 in Dhh-expressing cell(s) causes neurofibroma
formation.
To determine whether any cell types in addition to glial cells
expressed Dhh at some time in their history, we first indirectly
assessed the status of the Nf1 gene in multiple cell types in the
Nf1flox/flox; DhhCre; EGFP mouse sciatic nerves by determining
which cell types express EGFP. As shown in Figure 5, all of the
EGFP-positive cells are negative for the endothelial marker von
Willebrand Factor (vWF) and for the mast cell marker FcE RI
in P80 Nf1flox/flox;DhhCre; EGFP sciatic nerves. As shown in
Figure 2, perineurial fibroblasts are EGFP-negative in P1 and
P90 sciatic nerve, indicating that perineurial fibroblast cells are
unlikely to show recombination of Nf1.
To identify EGFP-expressing cells, we FACS sorted EGFP-
positive and -negative cells from Nf1flox/flox;DhhCre; EGFP
mouse P1/P2 sciatic nerves and from Nf1flox/flox;DhhCre; EGFP
neurofibromas. In the sorted tumor cells, all EGFP-positive cells
expressed p75 (79/79). Sixty-four percent of the EGFP negative
cells (272/425) were also p75-positive. P75 marks neural crest-
derived Schwann cells and their progenitors in nerve, but also
stains nerve axons and mast cells (Jippo et al., 1997; Obata
et al., 2006). Endoneurial fibroblasts derive from the neural crest,
and a shared glial-endoneurial fibroblast progenitor expresses
Dhh (Joseph et al., 2004). A specific endoneurial fibroblast
marker has not been described but endoneurial fibroblasts
lose p75 after differentiation (Joseph et al., 2004). To more spe-
cifically identify the p75+;EGFP+ cells, FACS sorted EGFP+ cells
were cytospun and stained for the Schwann cell marker S100b,
which marks immature and mature Schwann cells. In EGFP+
tumor cells, 94.5% (433/458) of the cells were S100b+. EGFP+
FACS sorted P1/P2 sciatic nerve cells were 98.1% (370/377)
S100b+. We also tested whether significant numbers of precur-
sor/immature Schwann cells are present in the nerves or tumors
of Nf1flox/flox;DhhCre mice by FACS sorting P1/P2 sciatic nerve
cells or tumor cells and staining with anti-Blbp antibody, an early
glial cell lineage marker. Interestingly, 47.5% and 53.3% of these
sorted EGFP+ cells are Blbp+;S100b+ in P1/P2 (Figures 5I–5L)
and tumor cells (Figures 5M–5P), respectively. Thus, p75+;
S100b+ cells express EGFP. The expression of Blbp in many of
the cells supports the idea that they are similar to immature
Schwann cells as identified by Jessen and Mirsky (2005). Figure 7
shows the relative expression of these markers in normal cells.
Because EGFP expression indirectly measures inactivation of
the Nf1 gene, we also dissociated cells from neurofibromas from
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endothelial cells (CD31+/CD45) or mast cells (c-kit+/ FcE RI+)
from the dissociated tumor cells. As a positive control, we sorted
EGFP-positive cells (putative immature Schwann cells [Jessen
and Mirsky, 2005]) from EGFP;Nf1flox/flox;DhhCre mouse P1/P2
sciatic nerve cells. We carried out PCR reactions using primers
for the nonrecombined or recombined Nf1 alleles on these
sorted cells. Only the P1/P2 nerve-derived EGFP+ cells showed
Nf1 recombination (Figure 5R). Both endothelial cells and mast
cells maintained Nf1flox/flox (wild-type) status (Figure 5Q).
Because Schwann cells with Nf1 mutations have been reported
to express c-kit (Ryan et al., 1994), we confirmed the results
by PCR genotyping of bone marrow-derived mast cells from
these mice. After 5 weeks of culture, >98% of the cells showed
metachromatic granules characteristic of mast cells. These
Figure 5. Only p75+ Cells Recombine Nf1 in Nf1flox/flox;DhhCre
Mouse Nerves and Tumors
EGFP expression (B and D) in sections from adult Nf1flox/flox;DhhCre;EGFP sci-
atic nerves cryo-sectioned and stained with anti-von Willebrand factor to mark
endothelial cells (red, [A]), or anti-IgE Fc receptor to mark mast cells (red, [C]).
(B) and (D) show merged images of EGFP fluorescence and immunostains.
FACS-sorted EGFP+ (E and F) and EGFP (G and H) cytospun cells were im-
munostained with anti-p75 antibodies (E and G). All EGFP+ cells are p75+, but
some EGFP are p75+ while other are p75 cells (white arrows, [H]). FACS-
sorted EGFP+ cells from P1/P2 sciatic nerves (I–L) or tumor were stained
with Blbp (red, [I and M]) and S100b (green, [J and N]). Scale bars in (A)–(P),
13 mm. FACS sorted cells from P1 sciatic nerve or tumor were analyzed for
Cre-mediated recombination of Nf1 by PCR (Q and R). (Q) Endothelial cells
(CD31+/CD45; EC) or mast cells (c-kit+/IgEFcR+; MC) from dissociated tu-
mor cells did not recombine Nf1. DNA from cells from two Nf1flox/flox;Dhh-
Cre;EGFP tumors (T1 and T2) show recombination. Nf1fl allele, FL/FL; recom-
bined Nf1 allele, R-Cre. (R) Postnatal day 1 EGFP+ cells (EGFP+) showed Nf1
recombination, as did tumor DNA (T1). Water is shown as a negative control.mast cells derived from bone marrow progenitors also main-
tained Nf1flox/flox (wild-type) status (data not shown).
Nf1flox/flox;DhhCre Mice Exhibit Increased Schwann
Cell Proliferation in Sciatic Nerves and Disruption
of Axon-Glial Interactions in Peripheral Nerves
Hyperproliferative nonneoplastic lesions have been described in
various tumors and can provide insight into the biology of early
tumor formation. We cut paraffin sections of nerves from
Nf1flox/flox;DhhCre mice. In histological sections, these changes
do not satisfy criteria for diagnosis of GEM-neurofibroma when
these mice were 6.5 months old (Figures 6A and 6B). However,
the enlarged nerves in Nf1flox/flox;DhhCre are not normal, but
show disorganization on histological section confirmed by elec-
tron microscopy, with loss of association between axons and
nonmyelin-forming Schwann cells (Figures 6C and 6D). Specifi-
cally, the Remak bundles (bundles of small axon diameter within
membrane-delineated cytoplasm of a nonmyelinating Schwann
cell; arrows in Figures 6C and 6D) are well defined in nor-
mal nerves but not Nf1flox/flox;DhhCre nerves. The disruption of
axon-Schwann interaction in these nerves is similar to that
observed in tumors (see Figures 4G–4I).
To determine whether tumor formation is preceded by cell
division in the Nf1flox/flox;DhhCre model, we injected mice prior
to sacrifice with BrdU and analyzed tissue sections by staining
with anti-BrdU and p75. Proliferation of cells was measured in
P1, P15, and P60 sciatic nerves and GEM-plexiform neurofi-
bromas. Proliferation of BrdU+;p75+ cells in tissue sections in
the P1 and P15 Nf1flox/flox;DhhCre mouse sciatic nerves was
increased 3.2-fold and 4.5-fold compared to nerves from wild-
type littermates. Proliferation of BrdU+;p75+ cells in tissue sec-
tions in the P60 Nf1flox/flox;DhhCre mouse sciatic nerves did not
differ from normal (Figure 6E). In tissue sections from P15 nerve,
we did not detect Blbp expression (data not shown), indicating
that most cells have matured into differentiated Schwann cells
at this later stage. We also measured apoptosis in P15 mice
sciatic nerves. There was no significant difference in TUNEL+
sciatic nerve cells from Nf1flox/flox;DhhCre mice as compared to
littermate controls (p = 0.42, n = 4, Figure 6F).
To definitively determine if the BrdU+ cells are Schwann cells,
we FACS sorted BrdU+;EGFP+ or BrdU+;EGFP- cells from
Nf1flox/flox;DhhCre;EGFP P1/P2 mouse sciatic nerves. We cyto-
centrifuged the cells and stained for S100b. All BrdU+/EGFP+
cells were S100b+, indicating these proliferating cells are
Schwann cells (Figure 6G, I, J). BrdU+/EGFP- cells in P1/P2 sci-
atic nerve were also S100b+, suggesting affects of the abnormal
nerve environment on surrounding cells. Alternatively, DhhCre
may have elicited Nf1 but not EGFP recombination in these cells.
WealsomonitoredBrdU incorporation inGEM-neurofibroma.Cell
division varied greatly from region to region within neurofibromas,
ranging from 1.4% to 29.9% of cells, even within the same tumor
(Figure S1). Thus tumor formation in this model is preceded by
disruption of Remak bundles and early but transient nerve Schwann
cell proliferation. Proliferation resumes in the GEM-neurofibromas.
DISCUSSION
Our results support the relevance ofNf1 inactivation in aDhh-ex-
pressing precursor cell to development in mice of manifestationsCancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc. 111
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dorsal root ganglion-derived cells in vitro at embryonic day
12.5 + 1 results in colony formation, while inactivation of Nf1 in
Figure 6. Nf1flox/flox;DhhCre Mouse Nerves Show Disrupted
Morphology and Transiently Increased Schwann Cell Proliferation
Paraffin sections from 6.5-month-old wild-type (A) and Nf1flox/flox;DhhCre (B)
mouse sciatic nerves. Scale bars in (A) and (B), 50 mm. Electron micrograph
from wild-type (C) and Nf1flox/flox;DhhCre (D) saphenous nerve. Black arrows
in (C) indicate well-organized wild-type non-myelinated axons; those in (D)
show disorganized nonmyelinated axons. Scale bars in (C) and (D), 10 microns.
(E) Quantification of BrdU positive cells in Nf1flox/flox;DhhCre P1, P15, and P60
sciatic nerves (white bars) and wild-type littermate controls (black bars). Pro-
liferation in theNf1flox/flox;DhhCremouse nerve compared to wild-type controls
differs significantly in P1 sciatic nerves (p < 0.01, n = 3) and P15 sciatic nerves
(p < 0.001, n = 3), but not in P60 sciatic nerves (p = 0.17, n = 3). Data analyzed
by Student’s t test are presented as mean values ± standard deviation. (F)
Quantification of apoptotic cells in Nf1flox/flox;DhhCre P15 sciatic nerves (white
bars) and wild-type littermate controls (black bars). There is no significant dif-
ference in TUNEL staining between Nf1flox/flox;DhhCre mice and their litter-
mates (p = 0.42, n = 4, data analyzed by Student’s t test are presented as
mean values ± standard deviation). A representative image of double staining
is shown in (I) (BrdU, red; P75, green). (G) FACS analysis of BrdU-labeled P1/
P2 Nf1flox/flox;DhhCre sciatic nerve cells indicating BrdU+/EGFP+ and BrdU+/
EGFP cells (G and H). (J) Sorted BrdU+/EGFP+ cells are S100b positive (red).112 Cancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc.neural crest cells or in mature Schwann cells does not. In vivo,
inactivation of the Nf1 gene by the DhhCre driver beginning at
E12.5 elicits plexiform neurofibromas, dermal neurofibromas,
and pigmentation.
Nf1 inactivation in the neural crest is apparently not required
for neurofibroma formation. In vitro, colony formation of neural
crest cells does not occur following acute loss of Nf1, and the
DhhCre driver is not expressed in neural crest cells in vivo.
Neural crest drivers Mpz-Cre (E9.5 to E10.5 in the region of the
presumptive DRG), Pax3-Cre (E10.5 in dorsal neural tube and
the region of the presumptive DRG), and Wnt1-Cre (E9.5 in mi-
grating neural crest) also did not elicit neurofibroma formation
in Nf1flox/flox mice (Gitler et al., 2003).
What is the postneural crest target cell in which Nf1 inactiva-
tion causes plexiform neurofibroma formation in vivo? The para-
spinal region contains nerve roots, the dorsal root ganglion, and
the proximal part of the peripheral nerve and is the site of most
plexiform GEM-neurofibromas in the Nf1flox/flox;DhhCre model
(Figure 7). The neural crest-derived glial cells in this region are
boundary cap cells and embryonic Schwann cells. The DRG
also contains satellite cells derived from neural crest and bound-
ary cap cells, which we tentatively exclude. Although cells within
the DRG expressed DhhCre as assessed by EGFP expression,
cells with the morphology of satellite cells (apposed to neuronal
somata) did not. Rather, the few DRG cells expressing EGFP
expressed the Schwann cell marker S100b, not expressed by
satellite cells, and had the morphology of Schwann cells with lin-
ear processes apposed to nerve axons. However, until a specific
satellite cell marker is available for mouse, we cannot formally
Figure 7. Proposed Model of Neurofibroma Initiation in the Neural
Crest-Derived Glial Lineage
In the paraspinal region of the trunk, migrating neural crest (NC) cells (E8.5 to
E9) give rise to boundary cap (BC) cells (E10.5 to E11) in the spinal roots and
Schwann cell precursors (SCP, E12 to E13) in the peripheral nerve. The dia-
gram shows a crest cell and general appearance of the nerve at subsequent
developmental stages. Markers used in this report and expression over time
are designated by horizontal boxes (P75, Dhh, Blpb, S100b, Gfap). We place
the neurofibroma-initiating cell at the Schwann cell precursor/immature
Schwann cell boundary.
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recombination.
A possible target cell population is boundary cap cells in the
spinal roots of the mouse trunk, present by day E10.75. Bound-
ary cap cells develop into dorsal root glial (Schwann-like) cells,
some DRG neurons and satellite cells, and proximal Schwann
cells of peripheral nerve based on expression of Egr2/Krox20
(Maro et al., 2004), consistent with our finding of tumors in these
locations. It is not yet known whether some distal nerve Schwann
cells derive from boundary cap cells. Like Schwann cell progen-
itors, with neuregulin-induced differentiation, in vitro boundary
cap cells become Schwann cells (S100b+; Mbp+) capable of
myelination (Aquino et al., 2006). The hypothesis that boundary
cap cells are a target for tumorigenesis is consistent with the ob-
servation that plexiform neurofibromas form, albeit in an Nf1+/
genetic background, when theKrox20Cre driver is used to ablate
Nf1 (Zhu et al., 2002). A detailed comparison of the Nf1flox/flox;
Krox20-Cre and Nf1flox/flox;DhhCre models is shown in Table S1
available with this article online.
Embryonic and immature Schwann cells also expressDhh (Bit-
good and McMahon, 1995; Jessen and Mirsky, 2005; Parmantier
et al., 1999). While defined in sciatic nerve, similar cells are likely
to exist in all peripheral and cranial nerves. The relevance of these
cells to neurofibroma formation is consistent with the placement
of some neurofibromas distal to the DRG in theNf1flox/flox;DhhCre
model. Schwann cell precursors are present in mouse sciatic
nerve beginning at E12.5 and have been referred to as neural
crest stem cells because in vitro and when transplanted into
avian hosts, they can develop into neurons, Schwann cells, and
SMA+ fibroblasts (Morrison et al., 1999; White and Anderson,
1999; White et al., 2001). However, in vivo, they are restricted
to Schwann cell or endoneurial fibroblast lineages as shown by
fate-mapping in vivo (Joseph et al., 2004). We use the term
Schwann cell precursor here to distinguish them from BC cells
and migrating neural crest cells. Supporting Schwann cell pre-
cursors as a target for tumorigenesis, in the Nf1flox/flox;DhhCre
model, nerves containing Schwann cells derived from Schwann
cell precursors are hypertrophied throughout their lengths,
show elevated proliferation, and disrupted organization including
mast cell recruitment and loss of axon-glial interaction. However,
tumors do not form in nerves. The environment surrounding the
DRG may facilitate tumor formation, or boundary cap cells may
be the only cells with tumorigenic potential.
We defined the neurofibroma-initiating cell using markers of
Schwann cell precursors and their progeny (Jessen and Mirsky,
2005). Markers for stages in boundary cap cell development
have not been delineated. Our analysis places the neurofi-
broma-initiating cell at the Schwann cell precursor/immature
Schwann cell boundary based on (1) tumor formation subsequent
to DhhCre expression; (2) Blpb, S100b, and Gfap expression
concomitant with absence of bIII-tubulin expression in EGFP-
expressing cells in peripheral nerves; and (3) the ability of E12.5
+ 1 D.I.V cells in vitro to form colonies and the evidence that
they are biopotent (Figure 7). While we cannot completely ex-
clude the relevance of a progenitor with wide potential in the
Nf1flox/flox;DhhCre model, our inability to detect Nf1 recombina-
tion in vivo in p75-negative cells, which should include endoneu-
rial fibroblasts (Joseph et al., 2004), is consistent with a more
restricted progenitor (see below).Neurofibromas formed under the skin in association with small
nerves in 48% of Nf1flox/flox;DhhCre mice. In humans, cutaneous
and subcutaneous neurofibromas, some of which are called der-
mal neurofibromas, form mainly beginning at puberty. In the
Nf1flox/flox;DhhCre mice, visible dermal tumors developed in
only adults. Another difference from human NF1 patients is
that the mouse dermal tumors rarely raised the skin. This likely
reflects the presence of the panniculus carnosus muscle under
the epidermis in mouse, but not in human. We designate these
Nf1flox/flox;DhhCre tumors GEM-dermal neurofibromas to distin-
guish from GEM-plexiform neurofibromas, but recognize their
position is not precisely identical to any one category of human
neurofibroma.
The progenitor cell for dermal GEM-neurofibroma may be the
hair follicle neural crest-derived cells with stem cell features,
recently shown to express Dhh (Fernandes et al., 2004; Sieber-
Blum et al., 2004; Wong et al., 2006). The normal role of these
cells is postulated to be replenishing neural crest derived mela-
nocytes in skin. We often observed melanocytes near tumors in
the Nf1flox/flox;DhhCre mice, and grafting E12.5 Nf1/ DRG-
derived cells into nerve generated pigmented melanocytes (Rizvi
et al., 2002). Some data support the existence of a postneural
crest bipotential glial-melanocyte progenitor cell (Le Douarin
and Dupin, 2003). A study of a patient who was somatic mosaic
for NF1 mutation in whom cafe´-au-lait macule melanocytes
and neurofibroma Schwann cells shared identical biallelic NF1
mutations supports a role for such a progenitor in human NF1
(Maertens et al., 2007).
Inactivation of Nf1 using DhhCre enables tumor formation in
the absence of an Nf1+/ background. In a previous study, plex-
iform neurofibromas were detected in an Nf1-driven mouse
model, but only in the presence of an Nf1+/ genetic background
(Zhu et al., 2002). In some, but not all, instances, an Nf1+/ envi-
ronment may contribute to neurofibroma formation. Another al-
ternative, which we favor, is that because the Krox20-Cre driver
is expressed in developing boundary cap cells beginning at
E10.5 and is not expressed in embryonic Schwann cells (Maro
et al., 2004), this driver does not cause Nf1 loss in a sufficiently
large pool of glial cell progenitors, so that an Nf1+/ genetic
background enhances the target cell pool. In either case, Nf1+/
perineurial cells, Nf1+/ mast cells, and Nf1+/ endothelial cells
are not always required for neurofibroma formation.
A model in which mice routinely develop GEM-neurofibroma
allowed us to study the histology of nerves prior to tumor forma-
tion. We found that interactions between Schwann cells and
axons in Remak bundles are dramatically perturbed. The finding
that neurofibromas in NF1 patients more frequently form on
sensory roots with many Remak bundles as compared to
motor nerve roots is consistent with a pronounced effect on non-
myelin-forming Schwann cells. Furthermore, Schwann cell pro-
liferation, normally very low in postnatal nerves, is transiently
increased in the first postnatal weeks in the Nf1flox/flox;DhhCre
mice. Transient proliferation was also reported in a mouse in
which the EGFR was expressed in Schwann cells (Ling et al.,
2005; Wu et al., 2006). Nerves from NF1 patients have not
been analyzed, precluding direct comparison between the spe-
cies. The relationship between proliferating cells in GEM-neuro-
fibromas and proliferating cells within nerves also remains to be
determined.Cancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc. 113
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in post neural crest cells expressing Dhh can cause neurofi-
broma formation, and provide a model to study neurofibroma
formation and test therapies.
EXPERIMENTAL PROCEDURES
Animals
We housed mice in a temperature- and humidity-controlled vivarium on a 12 hr
dark-light cycle with free access to food and water. The animal care and use
committee of Cincinnati Children’s Hospital Medical Center approved all
animal use. The Nf1flox/flox mouse has been described previously (Zhu et al.,
2002) and was on a mixed background 129/BL/6 background. The DhhCre
transgenic mouse line was generated on the FVB/N background, rederived,
and maintained on the CD1 (I129/BL/6) background for several generations
(Jaegle et al., 2003), then maintained by breeding with C57BL/6. We bred
DhhCre mice onto Nf1flox/flox background to obtain the F1 generation
(Nf1flox/+;DhhCre/+); we bred F1 mice with Nf1flox/flox mice to obtain
Nf1flox/flox;DhhCre mice. We bred a b-actin flox/stop/flox-EGFP mouse reporter
line maintained on C57BL/6 (Nakamura et al., 2006) onto the Nf1flox/flox
background to obtain the EGFP- Nf1flox/flox mice. We genotyped mice by
PCR as described (Jaegle et al., 2003; Nakamura et al., 2006; Zhu et al.,
2002). Littermates were used for controls. For analysis of embryos, we estab-
lished timed pregnancies with the morning of a vaginal plug defined as E0.5.
Cell Culture
We dissected E8.5 neural tubes from Nf1flox/flox embryos (Zhu et al., 2002),
allowed neural crest cells to migrate from the neural tubes plated on poly-
(L)-lysine (PLL) and fibronectin-coated or PLL and laminin coated dishes tissue
culture dishes, in DMEM + 10% FBS and 1% pen/strep. After 24 hr, neural
tubes were carefully removed (Williams et al., 2004). Cells remaining on the
substrate were infected with adenovirus (see below) and medium changed
to DMEM: F-12 (1:1) with N2 supplements (Invitrogen; Carlsbad, CA) and
50 mg/ml gentamycin. We established cultures from Nf1flox/flox embryos by dis-
sociating cells from E12.5 DRG as described (Ratner et al., 2005) and plated
cell suspensions on PLL and laminin coated dishes for 16 hr prior to adenoviral
infection in DMEM: F-12 (1:1) with N2 supplements (Invitrogen) and 50 mg/ml
gentamycin. To study Schwann cells, we exposed cells from E12.5 DRG to
b-heregulin (10ng/ml) and forskolin (1mM) for 7 days in DMEM: F-12 (1:1)
with N2 supplements (Invitrogen) and 50 mg/ml gentamycin, on PLL and lam-
inin coated dishes, before infection with adenovirus (Kim et al., 1997). After
infection, we monitored cultures from each time point for colony formation.
We trypsinized and replated colonies that arose in E12.5 cultures.
Differentiation Assays
We passaged Adeno-Cre infected E12.5 DRG Nf1flox/flox cells that grew as
colonies, plated on PLL and laminin, and exposed to cells in basal medium
of DMEM + 10% FBS + 1% Pen/Strep, with lineage-driving growth factors
(Fernandes et al., 2004; Stemple and Anderson, 1993; Wong et al., 2006).
For neurogenesis, we cultured cells for 5 days with bFGF (20 ng/ml) followed
by 7 days with BDNF, NT3, NGF (10 ng/ml each). Gliogenic conditions were
b-heregulin and forskolin (5 ng/ml and 2 mM, respectively) for 12 days. Smooth
muscle/myofibroblast-generating culture assays included TGF-b1 (1 ng/ml) for
12 days. Cells were then fixed and stained with rat anti-MBP (1:100 Serotec,
Raleigh, NC), mouse anti-b3tubulin (1:200, Chemicon, Temecula, CA) or
mouse anti-smooth muscle actin (SMA) (1:500, Sigma-Aldrich, St. Louis,
MO), and appropriate secondary antibodies.
Adenovirus Infection
Cells were exposed to CsCl2-purified Cre adenovirus for 2 hr in DMEM + 1%
FBS, then returned to normal growth medium. We infected cells with a range
of concentrations of virus to generate 80%–90% infected cells as assessed
by expression of EGFP. For Schwann cells, a multiplicity of infection of 100 MOI
generated EGFP+ cells and recombination. This concentration of virus is toxic
to E12.5 cells and neural crest cells, which required a moi of 10. Cells in colo-
nies were stained with anti-Blbp (1:1000).114 Cancer Cell 13, 105–116, February 2008 ª2008 Elsevier Inc.Fluorescence-Activated Cell Sorting
We generated cell suspensions of GEM-neurofibroma by incubation in
0.5 mg/ml collagenase (Worthington, Lakewood, NJ) and 2.5 mg /ml dispase
II (Roche) for 4 hr. After two washes in ice-cold PBS, we strained cells through
a 70 mm cell strainer (Becton Dickinson; San Jose, CA). We incubated cells with
anti-mouse CD45 (Becton Dickinson) bound to allophycocyanin (APC), CD31
(Becton Dickinson) bound to phycoerythrin (PE), CD-117 (c-kit, Becton Dick-
inson) bound to APC, and/or rat anti-mouse FcE RI (eBioscience, San Diego,
CA) bound to PE on ice in a solution containing PBS/0.2% BSA for 30 min. After
washing, we resuspended cells in PBS/0.2% BSA/2 mg/ml 7-aminoactinomy-
cin D (7-AAD, Invitrogen). We carried out isotypic controls containing irrelevant
mouse-IgG1-APC and mouse-IgG1-PE in parallel. Cells were acquired in a
FACSVantage DiVa equipped with a 488 nm Argon laser, a 633 nm HeNe laser,
and a tunable Argon-UV laser (Becton Dickinson). For EGFP tagged GEM-
neurofibroma cells, we sorted the cells directly to identify EGFP-high and
-negative cells. A total number of 53 106 cells were sorted in each experiment.
For BrdU FACS, P1/P2 Nf1flox/flox; DhhCre; EGFP mice were injected (intra-
peritoneally) with bromodeoxyuridine (BrdU, Sigma-Aldrich) in water (50 mg
BrdU per kg of body weight) three times at 2 hr intervals (total 6 hr) before
sacrifice. Sciatic nerves were dissected and cells dissociated. We fixed,
permeabilized, and stained cells with APC-conjugated anti-BrdU (1:50, BD
Biosciences, San Jose, CA) according to the manual and FACS sorted
BrdU+/EGFP+ or BrdU+/EGFP cells as above.
Histology
We perfused mice intracardially with 4% paraformaldehyde (w/v) in PBS. We
dissected, cryoprotected, and cut sciatic nerves into 12-mm sections for
immunofluorescence staining (Ling et al., 2005; Wu et al., 2006). Sections
were stained with anti-von Willebrand factor (vWF) (Chemicon), anti-IgE FcR
I (CD23, Santa Cruz Biotechnology, Santa Cruz, CA), and anti-EGFP anti-
bodies (Invitrogen) overnight at 4C followed by incubation with FITC- or
TRITC-labeled appropriate secondary antibodies. We viewed sections with
a fluorescence microscope (Carl Zeiss, Thornwood, NY) equipped with a digital
imaging system. We embedded some tumor specimens in paraffin, cut 6 mm
paraffin sections, and stained with hematoxylin and eosin, toluidine blue,
Masson’s trichrome, or with anti-S100b (Dako, Carpinteria, CA) and HRP-con-
jugated goat anti-rabbit followed by diaminobenzidine reaction to highlight
Schwann cells.
Cell Proliferation
We injected mice intraperitoneally with BrdU (Sigma-Aldrich) in water (50 mg
BrdU per kg of body weight) three times at 2 hr intervals (total 6 hr) before
intracardiac perfusion. Sciatic nerves or tumors were dissected, paraffin-
embedded, and cut into 6 mm sections. Deparaffinized sections were treated
with 2 mol/l HCl for 30 min at 37C, blocked in PBS containing 0.15% Triton
X-100 and 5% donkey serum, and incubated with a rat anti-BrdU antibody
(1:200; Zymed Laboratories Inc., South San Francisco, CA) and rabbit anti-
p75 (1:500, Chemicon) overnight at 4C followed by TRITC- and FITC-conju-
gated secondary antibodies. We stained nuclei with 4,6-diamidino-2-phenylin-
dole (DAPI) (Sigma) for 5 min. We counted BrdU-labeled cells and blue nuclei
in at least three cross-sections made through each sciatic nerve. Data are
presented as average numbers of BrdU-labeled cells per section.
TUNEL Assay
TUNEL assay was performed according to Promega manual instruction by
DeadEnd Fluorometric TUNEL System (Promega, San Luis, CA) on deparaffi-
nized sections. Nuclei were stained with DAPI as described above. We
counted TUNEL-positive cells and the DAPI nuclei in at least three cross-
sections made through each sciatic nerve. Data are presented as average
numbers of TUNEL-positive cells per section.
Electron Microscopy
We perfused mice intracardially with Karnovsky’s fixation solution (3% para-
formaldehyde and 3% glutaraldehyde in 0.1 mol/l phosphate buffer, pH 7.4
to 7.6). We dissected saphenous nerves and embedded and evaluated them
as described (Ling et al., 2005; Wu et al., 2006).
Cancer Cell
Neurofibroma Formation in MiceSupplemental Data
The Supplemental Data include one supplemental figure, one supplemental
table, and one supplemental movie and can be found with this article online
at http://www.cancercell.org/cgi/content/full/13/2/105/DC1/.
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